|Application ||WB, IHC-P, FC, E|
|Calculated MW||57890 Da|
|Antigen Region||476-502 aa|
|Other Names||Melanoma antigen preferentially expressed in tumors, Opa-interacting protein 4, OIP-4, Preferentially expressed antigen of melanoma, PRAME, MAPE, OIP4|
|Target/Specificity||This MAPE antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 476-502 amino acids from the C-terminal region of human MAPE.|
|Precautions||MAPE Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Functions as a transcriptional repressor, inhibiting the signaling of retinoic acid through the retinoic acid receptors RARA, RARB and RARG. Prevents retinoic acid-induced cell proliferation arrest, differentiation and apoptosis.|
|Cellular Location||Nucleus. Cell membrane|
|Tissue Location||Expressed in testis. Detected in samples of kidney, brain and skin.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
MAPE is an antigen that is predominantly expressed in human melanomas and that is recognized by cytolytic T lymphocytes. It is not expressed in normal tissues, except testis. This expression pattern is similar to that of other CT antigens, such as MAGE, BAGE and GAGE. However, unlike these other CT antigens, its gene is also expressed in acute leukemias.
Rezvani,K., Blood 113 (10), 2245-2255 (2009)
Qin,Y., Leuk. Res. 33 (3), 384-390 (2009)
Neumann,E., Cancer Res. 58 (18), 4090-4095 (1998)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.